Pasithea Therapeutics Corp. (KTTA): Submission of Matters to a Vote of Security Holders
Pasithea Therapeutics Corp. (KTTA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 9, 2026, the Company held its Annual Meeting. The stockholders of the Company acted upon the following three proposals at the Annual Meeting: (1) the election of two Class III directors; (2) the ratifica
How this was made
The 30-second read
Why it matters
The approvals set the stage for a potential reverse split, which could alter share liquidity and price perception.
Market read
Primary disclosure with limited immediate trading impact; mainly of interest to current shareholders and micro‑cap traders.
What to watch
Board composition changes may signal upcoming strategic shifts or financing activities.
Background
Pasithea Therapeutics filed an 8‑K detailing actions taken at its annual meeting, including director elections and a reverse split proposal.
Ticker impact
SEC 8‑K reports approval of a reverse stock split and election of directors at the annual meeting.
Short‑term volatility expected; long‑term impact depends on split ratio and execution.
The filing is a primary disclosure but the material change (reverse split) is procedural and its financial effect is uncertain.
Market effects
Minimal; primarily affects micro‑cap biotech sector where reverse splits are common.
None
Low
Counterpoint
The reverse split could be a catalyst for a short squeeze if the ratio is favorable.
Key entities
- companyPasithea Therapeutics Corp.
Biotech firm filing the 8‑K.
- service_providerCBIZ CPAs P.C.
Appointed as independent registered public accounting firm.
